Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle c
about
Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemiaHigh-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adultsBendamustine for patients with B cell lymphoid malignanciesRetrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project DatabaMantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.Validation, revision and extension of the Mantle Cell Lymphoma International Prognostic Index in a population-based setting.Endoscopic features and prognoses of mantle cell lymphoma with gastrointestinal involvementIdentification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end pointsInitial therapy of mantle cell lymphomaActivation of the Constitutive Androstane Receptor Increases the Therapeutic Index of CHOP in Lymphoma TreatmentThe clinical features, therapeutic responses, and prognosis of the patients with mantle cell lymphomaFirst-line treatment of follicular lymphoma: a patient-oriented algorithm.Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma.Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modalityHematopoietic SCT for mantle cell lymphoma: is it the standard of care?Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis.Managing newly diagnosed follicular lymphoma: state of the art and future perspectives.Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group.Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation.Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective.Systematic review of the recent evidence for the efficacy and safety of chlorambucil in the treatment of B-cell malignancies.Chemotherapy and treatment algorithms for follicular lymphoma: a look at all options.Risk of chemotherapy-induced neutropenic complications when treating patients with non-Hodgkin lymphoma.Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL.Novel therapy for therapy-resistant mantle cell lymphoma: multipronged approach with targeting of hedgehog signaling.Follicular dendritic cells in follicular lymphoma and types of non-Hodgkin lymphoma show reduced expression of CD23, CD35 and CD54 but no association with clinical outcome.Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus.Effect of response quality and line of treatment with rituximab on overall and disease-free survival of patients with B-cell lymphoma.The G protein-coupled estrogen receptor 1 (GPER-1) contributes to the proliferation and survival of mantle cell lymphoma cells.Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD.ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma.Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide.A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma.Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma.FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.Oral arsenic trioxide-based regimen as salvage treatment for relapsed or refractory mantle cell lymphoma.
P2860
Q24200280-03B84E61-8DC3-4790-BAD3-373808601B11Q24203878-EB034A09-576D-4CA7-A793-70B008332B8AQ24236426-D84ADD7C-8154-447D-AEDC-A9FF4D52356BQ30649483-7B71C3B3-370C-484F-BB42-7AA6B0477EDFQ33586239-3FD37B38-2EA9-4D25-8FD5-A75A2A7EFAD1Q34095625-509E3B79-C0F6-489A-8EA1-67B2C6D12EA2Q34183167-17A9C3D0-8ACD-4BD6-AD04-C13B54FC3BB6Q35004750-79AD79C0-28E9-43D5-AB10-E350909FA612Q36612648-A2C16C8E-1C17-4029-950B-6F82B4356E4FQ36665092-219CC8AC-DC89-4290-93E3-395CDD9ABCEDQ37183720-A237B73C-3169-4528-AA05-6BA777435662Q37396916-0B8227E6-1908-4F62-ACF6-98D8DDD6BCF8Q37402853-5C222174-E07B-430C-8F81-E500C47AC5DAQ37498829-4F65546C-E032-420D-A7A8-FD5CBE6BBAA5Q37728866-6739E4AF-D5FF-47BC-ABD2-5A096652926BQ37970668-19D34AAA-2AD6-49F6-B97E-9ADB05D3FF00Q38088002-2A052615-695F-4BC9-8873-480014241635Q38110232-32936222-7B67-4770-9F12-F9BB742D0BF4Q38160456-7BB6CFFC-56CE-4FA6-9BB9-62049B9C5B84Q38216650-3927EA01-B95F-41B8-8DC4-8ABE724317A1Q38574045-259474FD-571B-489C-86E9-1CD69DC66BE6Q38594531-E3BEE3C5-03CD-46D4-8435-A4A1A1C048B8Q38711166-8A43B4DF-BF9C-4010-A261-E4F61C568B51Q38818397-A199BE57-EC33-44C7-99E9-4452BAA6E399Q39363109-25FEE7B4-13C0-461A-8925-0F1D9DA0B631Q39974868-855F74AE-244D-4575-A8AA-C1F4EE049ABFQ41085672-BFED6287-11E6-421A-8812-C8D394B167D0Q42284554-97819D8A-C006-462D-B416-E5B19D4A5473Q42910841-8AD75A44-477B-4BBB-AB6F-E5411CDCD3DFQ44872919-03E01003-049D-4707-8496-6589342B7FBBQ45124918-9FF0B748-0BC5-49B4-A0D9-EE3E3F24A076Q45951618-F5101866-3279-4512-BA58-7A6DBE90264AQ46830943-0B8D23F7-DABD-4DF6-AE9D-110950DDC51CQ47141499-731FE787-2158-4C43-89FD-C1B659C6F546Q47419522-21DEDF66-86A4-4528-94F6-708AA3B557E3Q51146815-8AE0B29A-A602-42BF-ADC9-7F017DC95D4B
P2860
Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle c
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Combined cyclophosphamide, vin ...... CP) in follicular and mantle c
@ast
Combined cyclophosphamide, vin ...... CP) in follicular and mantle c
@en
type
label
Combined cyclophosphamide, vin ...... CP) in follicular and mantle c
@ast
Combined cyclophosphamide, vin ...... CP) in follicular and mantle c
@en
prefLabel
Combined cyclophosphamide, vin ...... CP) in follicular and mantle c
@ast
Combined cyclophosphamide, vin ...... CP) in follicular and mantle c
@en
P2093
P356
P1433
P1476
Combined cyclophosphamide, vin ...... CP) in follicular and mantle c
@en
P2093
Christina Nickenig
Eva Lengfelder
German Low-Grade Lymphoma Study Group
Hannes Wandt
Lorenz Trumper
Marcel Reiser
Martin Dreyling
Michael Unterhalt
Wolfgang Hiddemann
P304
P356
10.1002/CNCR.22093
P407
P577
2006-09-01T00:00:00Z